Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
Howland E. Crosswell,
Ann S. LaCasce,
Nancy L. Bartlett,
David J. Straus,
Kerry J. Savage,
Pier Luigi Zinzani,
Graham P. Collins,
Michelle Fanale,
Keenan Fenton,
Cassie Dong,
Harry Miao,
Andrew P. Grigg
Affiliations
Howland E. Crosswell
Bon Secours Hematology and Oncology, Bon Secours, St. Francis Health System, Greenville, SC
Ann S. LaCasce
Dana-Farber Cancer Institute, Partners Cancer Care, Boston, MA
Nancy L. Bartlett
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO
David J. Straus
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Kerry J. Savage
British Columbia Cancer Agency, Vancouver, BC
Pier Luigi Zinzani
IRCCS University Hospital of Bologna, Institute of Hematology “Seràgnoli,” Bologna, Italy; Department of Specialized Medicine, Diagnostic and Experimental, University of Bologna, Bologna
Graham P. Collins
Oxford University Hospitals NHS Foundation Trust, Oxford
Michelle Fanale
Seagen Inc., Bothell, WA
Keenan Fenton
Seagen Inc., Bothell, WA
Cassie Dong
Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
Harry Miao
Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
Andrew P. Grigg
Department of Clinical Haematology, Austin Hospital, VIC
